RT Journal Article
SR Electronic
T1 Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 829
OP 834
DO 10.21873/anticanres.14835
VO 41
IS 2
A1 NAKAMURA, MASAKI
A1 KAGEYAMA, SHUN-ICHIRO
A1 SEKI, MASAHIDE
A1 SUZUKI, AYAKO
A1 OKUMURA, MASAYUKI
A1 HOJO, HIDEHIRO
A1 MOTEGI, ATSUSHI
A1 AKIMOTO, TETSUO
YR 2021
UL http://ar.iiarjournals.org/content/41/2/829.abstract
AB Background/Aim: To investigate the usefulness of cell-free DNA (cfDNA) in patients with oligometastasis. Patients and Methods: This study included oligometastatic colorectal cancer (CRC) patients who underwent ablative irradiation using stereotactic body radiotherapy or proton beam therapy for metastatic lesions at a single institution. cfDNA was purified from the plasma of pretreated patients and gene mutations were analyzed by next-generation sequencing. Progression-free survival (PFS) was statistically compared according to gene mutation, clonality or allele frequency. Results: A total of 20 patients were analyzed. Mutations were detected in the following genes; TP53 (45%), APC (40%), KRAS (15%), PIK3CA (15%), NF1 (5%), BRCA1 (5%), ERBB2 (5%), FBXW7 (5%), KIT (10%), and HRAS (10%). Patients with multi-clonality of gene mutation showed tendency for poor PFS (p=0.07). Among 7 patients whose metastatic site was the lung, those with no cfDNA detected had significantly better PFS than those with cfDNA (p=0.02). Conclusion: cfDNA profiles could be predictive tools for early recurrence of oligometastatic CRC patients after ablative radiotherapy.